2,247 press releases in English indexed under biotech & pharma.
JUPITER, Fla., Oct. 16, 2026 -- Myosin Therapeutics today announced that, following its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives Showcase Company, it has been invited to present at BioFuture 2026, taking place October 27–28 in New...
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA PARIS, October 16, 2026--Regulatory News: GenSight Biologics (the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and
Peer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation CULVER CITY, Calif., October 16, 2026--ImmunityBio, Inc. ( NASDAQ: IBRX ), a commercial-stage immunotherapy company, today announced the publication of long-term d
TOKYO, October 16, 2026 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2026, taking place in Madrid from October 23 to
Cotecna, a leading provider of Testing, Inspection and Certification (TIC) services, today announced the acquisition of Energon Labs, a cGMP-compliant, USFDA-inspected, ISO 9001:2015 and ISO 17025:2017 certified analytical testing laboratory based in Hyderabad, India.
Delray Beach, FL, Oct. 16, 2026 -- MarketsandMarkets™ projects the global AI in drug discovery market to grow from USD 5.09 billion in 2026 to USD 17.56 billion by 2031, at a CAGR of 28.1% during the forecast period. Market growth is driven by the growing pharmaceutical demand to reduce drug discovery timelines and R&D costs, increasing adoption of generative AI and foundation models, expanding availability of multi-omics datasets, and investments in AI-enabled drug discovery platforms. Increasing strategic collaborations between pharmaceutical companies and AI technology providers, coupled with advances in cloud computing, high-performance computing, and computational biology, are further boosting the adoption of AI across early-stage drug discovery.
By Japhet Gana, Group Head, Transaction Risk & Financial Crimes, Yellow Card I recently spent five days in Nairobi watching investigators, regulators, and virtual asset providers work through the same simulated scenarios in the same room, at a training run by the United Nations Office on Drugs and Crime. I walked in expecting a […]
The global Frankincense Extract Market is gaining momentum as consumers increasingly seek natural ingredients for personal care, wellness, aromatherapy, and pharmaceutical applications. Frankincense extract, derived from the resin of Boswellia trees, has a long history of use in traditional wellness ... Read more
SHENZHEN, China, October 16, 2026--Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") (SSE: 688321) today announced that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed with Chengdu Chipscreen Newway Biosciences Co., Ltd., has obtained IND
Houston, Texas--(October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential tests of its investigational brain-cancer platform as it pursues treatment options for patients facing some of the most difficult challenges in neuro-oncology. The company recently reported an early clinical update involving a critically ill three-year-old boy with an aggressive brain tumor who, after receiving investigational intranasal NEO100 through...